Novavax Inc vs Rent the Runway Inc — how do they compare? Novavax Inc trades at $7.93 (market cap $1.31B), while Rent the Runway Inc trades at $3.64 (market cap $122.65M). The key difference: Novavax Inc is far larger — about 10.7× Rent the Runway Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | RENT | |
|---|---|---|
Market Cap | $1.31B | $122.65M |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $9.39 |
52-Week Low | $6.22 | $3.01 |
Enterprise Value | $889.30M | $282.75M |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Rent the Runway (RENT) trades at $3.70, up 1.65% with a bullish technical signal. The company shows improving fundamentals with Q1 2026 revenue growth of 29.2% to $89.9M and narrowing losses. Despite negative equity of -$182.5M, valuation metrics appear attractive with P/E of 0.48 and P/S of 0.2. Recent leadership transition with Teri Bariquit as interim CEO brings fresh perspective to the subscription fashion platform.
The outlook remains cautiously optimistic with analyst consensus leaning buy (42%) though profitability challenges persist. Key opportunities include subscriber growth and margin improvement, while risks involve high debt load and competitive pressure. The stock offers speculative upside if the company can achieve projected 2026 profitability of $30M net income.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →